Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 266

Sort by

Sort Order Select

Journal Articles

End points and outcomes in follicular lymphoma: what should we measure, how, and why?

Mengyang Di, Matthew J. Maurer, Christopher R. Flowers

Blood (2025) 146 (15): 1802–1811.

https://doi.org/10.1182/blood.2024026978

Published: 2025

Journal Articles

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study

Blood blood.2025028848.

https://doi.org/10.1182/blood.2025028848

Published: 2025

Journal Articles

TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma

Blood blood.2024026919.

https://doi.org/10.1182/blood.2024026919

Published: 2025

Includes: Supplemental data

Journal Articles

Blunted CD40-responsive enhancer activation in CREBBP -mutant lymphomas can be restored by enforced CD4 T-cell engagement

Blood (2025) 146 (2): 191–205.

https://doi.org/10.1182/blood.2024026664

Published: 2025

Includes: Supplemental data

Journal Articles

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Blood (2025) 145 (8): 823–839.

https://doi.org/10.1182/blood.2024025366

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Blood (2024) 144 (19): 2063–2066.

https://doi.org/10.1182/blood.2024025681

Published: 2024

Includes: Supplemental data

Journal Articles

Radiation Therapy and Monocyte Activation in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy

Blood (2024) 144 (Supplement 1): 4377.

https://doi.org/10.1182/blood-2024-203844

Published: 2024

Journal Articles

Genomic and Spatial Proteomic Characterization of the Microenvironment of Diffuse Large B-Cell Lymphoma in African American Patients

Michelle J. Lee, Kumudha Balakrishnan, Arman Petrosyants, Daniil Wiebe, Chijioke Nze, Neha Akkad, Amy Ayers, James D. Ayres, Timothy J. McDonnell, Pavel Zemskiy, Kiril Kriukov, Alexander Nesmelov, Ksenia Zornikova, Krystle Nomie, Alexander Sarachakov, Nikita Kotlov, Ankur Singh, Jean L. Koff, Christopher R. Flowers

Blood (2024) 144 (Supplement 1): 4348.

https://doi.org/10.1182/blood-2024-210184

Published: 2024

Journal Articles

Use of Molecular Immune Signatures for Frontline Treatment Selection in Patients with Advanced Stage Follicular Lymphoma

Tony Z. Zhuang, Lei Feng, Dai Chihara, Chijioke Nze, Amy A. Ayers, Mansoor Noorani, James D. Ayres, Daniela E. Duenas, Kumudha Balakrishnan, Ekaterina Nesterenko, Mark Meerson, Ksenia Zornikova, Krystle Nomie, Nikita Kotlov, Nathan Fowler, Maria Alma Rodriguez, Sattva S. Neelapu, Christopher R. Flowers, Paolo Strati

Blood (2024) 144 (Supplement 1): 2982.

https://doi.org/10.1182/blood-2024-202654

Published: 2024

Journal Articles

Comprehensive Molecular Characterization of Monomorphic Post-Transplant Lymphoproliferative Disorder (PTLD)

Jean L. Koff, Kumudha Balakrishnan, Michael Churnetski, Michelle J. Lee, Anna Kurilovich, Svetlana Paponova, Alexander Nesmelov, Ksenia Zornikova, Pavel Zemskiy, Alexander Bagaev, Nikita Kotlov, Christopher R. Flowers

Blood (2024) 144 (Supplement 1): 5759.

https://doi.org/10.1182/blood-2024-209996

Published: 2024

Journal Articles

Tumor Genomics and Microenvironment Characterization of Diffuse Large B-Cell Lymphoma in Asian and Pacific Islander Patients

Michelle J. Lee, Kumudha Balakrishnan, Pavel Zemskiy, James D. Ayres, Timothy J. McDonnell, Neha Akkad, Kiril Kriukov, Arina Tkachuk, Ksenia Zornikova, Krystle Nomie, Aleksander Bagaev, Jean L. Koff, Christopher R. Flowers

Blood (2024) 144 (Supplement 1): 6209.

https://doi.org/10.1182/blood-2024-210739

Published: 2024

Journal Articles

Understanding the Patient Perspective on Treatment Preferences for Follicular Lymphoma

Mazie Tsang, Urshila Durani, Jonathan R Day, Melissa C. Larson, Matthew Holets, Kathleen J Yost, Jonathon B. Cohen, Jonathan W. Friedberg, Izidore S. Lossos, Peter Martin, Brad S. Kahl, Thomas M. Habermann, Loretta Nastoupil, James R. Cerhan, Christopher R. Flowers, Brian K. Link, Carla Casulo, Matthew J. Maurer

Blood (2024) 144 (Supplement 1): 7598.

https://doi.org/10.1182/blood-2024-210968

Published: 2024

Journal Articles

Clinical Trial Success Rate in Lymphoma: Fate of Trials and Agents from 2000 to 2023

Zhiping Luo, Meng Li, Christopher R. Flowers, Dai Chihara

Blood (2024) 144 (Supplement 1): 7597.

https://doi.org/10.1182/blood-2024-208810

Published: 2024

Journal Articles

Neighborhood-Level Social Determinants of Health and Cardiovascular Burden in Adolescent and Young Adult Patients Treated for Hodgkin Lymphoma

Elizabeth Rodriguez, Nader Kim El-Mallawany, Sairah Ahmed, Branko Cuglievan, John Andrew Livingston, Christopher R. Flowers, Qian Xiao, Michael E. Roth, Michelle A.T. Hildebrandt

Blood (2024) 144 (Supplement 1): 6359.

https://doi.org/10.1182/blood-2024-208944

Published: 2024

Journal Articles

T-Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis Has Worse Survival When Compared to T-Cell Lymphoma: A Retrospective Analysis from a Single Tertiary Center

Blood (2024) 144 (Supplement 1): 6420.

https://doi.org/10.1182/blood-2024-211482

Published: 2024

Journal Articles

Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Kunhwa Kim, Dai Chihara, Luis E. Fayad, Sattva S. Neelapu, Sairah Ahmed, Frederick Hagemeister, Chijioke Nze, Swaminathan P Iyer, Preetesh Jain, Michael Wang, Paolo Strati, Fateeha Furqan, Ayushi Chauhan, Michael R. Green, Christopher R. Flowers, Jason R. Westin

Blood (2024) 144 (Supplement 1): 4511.1.

https://doi.org/10.1182/blood-2024-205196

Published: 2024

Journal Articles

Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3038.

https://doi.org/10.1182/blood-2024-206042

Published: 2024

Journal Articles

Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study

Hun Ju Lee, Gregory Ravizzini, Eslam Aboismail, Jenna Wixom, Jared Henderson, Luis E. Fayad, Sairah Ahmed, Ranjit Nair, Jason R. Westin, Swaminathan P Iyer, Chijioke Nze, Ajlan Al Zaki, Francisco Vega, Michael Wang, Christopher R. Flowers, Luis Malpica

Blood (2024) 144 (Supplement 1): 1674.3.

https://doi.org/10.1182/blood-2024-212005

Published: 2024

Journal Articles

An Economic Analysis Assessing the Budget Impact of Introducing Glofitamab with Gemcitabine and Oxaliplatin for Autologous Stem Cell Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma to a United States Health Plan

David Fox, Katherine L Rosettie, Fadoua El Moustaid, Anthony Masaquel, Lourenia Cassoli, Christopher R. Flowers

Blood (2024) 144 (Supplement 1): 3646.

https://doi.org/10.1182/blood-2024-198451

Published: 2024

Journal Articles

Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma

Eduardo Edelman Saul, Bryan Valcarcel, Amy A. Ayers, Mansoor Noorani, Dai Chihara, Fateeha Furqan, Sairah Ahmed, Swaminathan P Iyer, Sattva S. Neelapu, Luis E. Fayad, F. B. Hagemeister, Chijioke Nze, Preetesh Jain, Michael Wang, Paolo Strati, Ayushi Chauhan, Francisco Vega, Christopher R. Flowers, Jason R. Westin

Blood (2024) 144 (Supplement 1): 4454.

https://doi.org/10.1182/blood-2024-211247

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

End points and outcomes in follicular lymphoma: what should we measure, how, and why?

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study

TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma

Blunted CD40-responsive enhancer activation in CREBBP -mutant lymphomas can be restored by enforced CD4 T-cell engagement

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Radiation Therapy and Monocyte Activation in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy

Genomic and Spatial Proteomic Characterization of the Microenvironment of Diffuse Large B-Cell Lymphoma in African American Patients

Use of Molecular Immune Signatures for Frontline Treatment Selection in Patients with Advanced Stage Follicular Lymphoma

Comprehensive Molecular Characterization of Monomorphic Post-Transplant Lymphoproliferative Disorder (PTLD)

Tumor Genomics and Microenvironment Characterization of Diffuse Large B-Cell Lymphoma in Asian and Pacific Islander Patients

Understanding the Patient Perspective on Treatment Preferences for Follicular Lymphoma

Clinical Trial Success Rate in Lymphoma: Fate of Trials and Agents from 2000 to 2023

Neighborhood-Level Social Determinants of Health and Cardiovascular Burden in Adolescent and Young Adult Patients Treated for Hodgkin Lymphoma

T-Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis Has Worse Survival When Compared to T-Cell Lymphoma: A Retrospective Analysis from a Single Tertiary Center

Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study

An Economic Analysis Assessing the Budget Impact of Introducing Glofitamab with Gemcitabine and Oxaliplatin for Autologous Stem Cell Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma to a United States Health Plan

Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only